(TRUP) Trupanion - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8982021060
TRUP: Pet, Insurance, Policies, Veterinary, Care, Plans
Trupanion, Inc., a leader in the pet insurance industry, provides medical coverage for cats and dogs through a subscription-based model. Operating across the United States, Canada, Continental Europe, and Australia, the company has established a strong presence in a growing market driven by increasing pet ownership and veterinary care expenses. Trupanions platform is designed to offer seamless claims processing, direct payments to veterinarians, and comprehensive coverage, distinguishing it in a competitive landscape.
Founded in 2000 under the name Vetinsurance International, Inc., Trupanion rebranded in 2013 to reflect its expanded vision and services. Headquartered in Seattle, Washington, the company has built a reputation for innovation and customer-centric solutions, attracting both pet owners and veterinary professionals. Its dual business segments—Subscription Business and Other Business—enable diversified revenue streams while maintaining a core focus on pet health insurance.
With a market capitalization of approximately $2.275 billion, Trupanion demonstrates significant growth potential. The forward P/E ratio of 1428.57 underscores investor confidence in its future prospects, despite current high valuations. A price-to-book ratio of 6.33 and a price-to-sales ratio of 1.63 highlight the markets expectation of sustained growth and profitability. These metrics are critical for investors assessing the companys value and competitive positioning in the expanding pet insurance sector.
Trupanions strategic focus on technology and data analytics enhances its ability to assess risks and offer personalized policies, which is vital in the insurance industry. The companys commitment to improving pet health outcomes aligns with broader trends in pet humanization and increasing expenditure on animal care. This convergence of factors positions Trupanion as a key player in a market with substantial growth potential, supported by a large total addressable market.
Additional Sources for TRUP Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
TRUP Stock Overview
Market Cap in USD | 2,276m |
Sector | Financial Services |
Industry | Insurance - Property & Casualty |
GiC Sub-Industry | Life & Health Insurance |
IPO / Inception | 2014-07-18 |
TRUP Stock Ratings
Growth 5y | 2.02% |
Fundamental | 28.8% |
Dividend | 0.0% |
Rel. Strength Industry | 6.87 |
Analysts | 4/5 |
Fair Price Momentum | 29.27 USD |
Fair Price DCF | 5.72 USD |
TRUP Dividends
No Dividends PaidTRUP Growth Ratios
Growth Correlation 3m | -80.5% |
Growth Correlation 12m | 85.7% |
Growth Correlation 5y | -51.6% |
CAGR 5y | 0.21% |
CAGR/Max DD 5y | 0.00 |
Sharpe Ratio 12m | 0.77 |
Alpha | 6.50 |
Beta | 1.83 |
Volatility | 64.70% |
Current Volume | 1785.2k |
Average Volume 20d | 647.6k |
As of February 23, 2025, the stock is trading at USD 32.95 with a total of 1,785,171 shares traded.
Over the past week, the price has changed by -33.61%, over one month by -30.47%, over three months by -37.42% and over the past year by +38.97%.
Neither. Based on ValueRay Fundamental Analyses, Trupanion is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 28.79 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TRUP as of February 2025 is 29.27. This means that TRUP is currently overvalued and has a potential downside of -11.17%.
Trupanion has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy TRUP.
- Strong Buy: 4
- Buy: 0
- Hold: 4
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, TRUP Trupanion will be worth about 35.1 in February 2026. The stock is currently trading at 32.95. This means that the stock has a potential upside of +6.59%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 56.7 | 72% |
Analysts Target Price | 56.7 | 72% |
ValueRay Target Price | 35.1 | 6.6% |